Article
Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia.
Arteriosclerosis, thrombosis, and vascular biology - 1 May 2001
Ylitalo K, Pajukanta P, Meri S, Cantor R M, Mero-Matikainen N, Vakkilainen J, Nuotio I, Taskinen M R
Abstract excerpt
A trapping defect of fatty acids due to impaired function of acylation-stimulating protein (ASP) has been suggested as one mechanism underlying the metabolic abnormalities in familial combined hyperlipidemia (FCHL). The study aimed at defining the role of ASP and complement C3 in 35 Finnish FCHL families. There was no difference in plasma ASP levels between the 66 hypertriglyceridemic FCHL patients and their 84...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.